Eli Lilly and Company (NYSE:LLY) Shares Purchased by First Long Island Investors LLC

First Long Island Investors LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% during the third quarter, HoldingsChannel reports. The firm owned 19,130 shares of the company’s stock after buying an additional 346 shares during the period. First Long Island Investors LLC’s holdings in Eli Lilly and Company were worth $16,948,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Simplify Asset Management Inc. boosted its position in Eli Lilly and Company by 67.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 19,082 shares of the company’s stock valued at $16,906,000 after buying an additional 7,670 shares during the last quarter. Altrius Capital Management Inc increased its stake in Eli Lilly and Company by 1.0% during the third quarter. Altrius Capital Management Inc now owns 1,285 shares of the company’s stock valued at $1,138,000 after purchasing an additional 13 shares during the last quarter. KCM Investment Advisors LLC raised its position in shares of Eli Lilly and Company by 1.0% during the 3rd quarter. KCM Investment Advisors LLC now owns 38,668 shares of the company’s stock worth $34,258,000 after purchasing an additional 394 shares during the period. Valley Wealth Managers Inc. grew its position in shares of Eli Lilly and Company by 26.4% during the third quarter. Valley Wealth Managers Inc. now owns 2,260 shares of the company’s stock worth $2,002,000 after acquiring an additional 472 shares during the last quarter. Finally, Empirical Finance LLC increased its stake in shares of Eli Lilly and Company by 2.4% in the third quarter. Empirical Finance LLC now owns 27,540 shares of the company’s stock valued at $24,399,000 after purchasing an additional 644 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on LLY shares. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Citigroup upped their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Sanford C. Bernstein started coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price for the company. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, BMO Capital Markets lifted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $1,007.94.

Eli Lilly and Company Stock Down 3.3 %

Shares of NYSE LLY traded down $25.64 during trading hours on Friday, hitting $760.59. The stock had a trading volume of 2,343,248 shares, compared to its average volume of 3,115,656. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market capitalization of $722.04 billion, a P/E ratio of 82.23, a P/E/G ratio of 3.07 and a beta of 0.43. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53. The firm’s 50-day moving average price is $885.79 and its two-hundred day moving average price is $869.71.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter last year, the company posted $0.10 EPS. The business’s revenue was up 20.4% compared to the same quarter last year. Analysts anticipate that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.68%. Eli Lilly and Company’s payout ratio is presently 56.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.